Who Should Not Take GLP-1 Medications?

GLP-1 medications can help some people manage type 2 diabetes or lose weight, but they are not suitable for everyone. A decision to use one should take account of medical history, other medicines, pregnancy plans, treatment goals, and the product’s approved labeling. These medicines are prescription treatments—not a shortcut or a substitute for appropriate medical care.

This article explains how GLP-1 receptor agonists work, what research and guidance say, who may need to avoid them or use them only with specialist advice, and what monitoring can involve. It is general information, not a personal diagnosis or treatment recommendation. Do not start, stop, or change a medication without speaking with your healthcare professional.

What are GLP-1 medications, and how do they work?

GLP-1 receptor agonists mimic the action of glucagon-like peptide-1, a hormone involved in blood-sugar regulation and appetite. Depending on the medication and its approved use, they can increase insulin release when blood sugar is high, reduce the release of glucagon, slow stomach emptying, and increase feelings of fullness. The combined effects may improve blood glucose and help some people eat less and lose weight.

Semaglutide is one medicine in this group. In the United States, Ozempic is a semaglutide product approved for certain adults with type 2 diabetes, while Wegovy is a semaglutide product approved for chronic weight management in eligible people and for certain other risk-reduction uses. They contain the same active ingredient but have different labeled indications and dosing. They are not interchangeable without a prescriber’s direction.

Not everyone responds the same way, and treatment is usually considered alongside nutrition, physical activity, behavioral support, and management of other health conditions. A clinician should confirm that a particular product is appropriate for the person and the intended use.

What do the STEP trials and other research show?

The STEP program included randomized controlled trials (RCTs) examining semaglutide for weight management in people with overweight or obesity. In STEP 1, participants without diabetes who received semaglutide 2.4 mg weekly alongside lifestyle support lost substantially more weight on average over 68 weeks than participants given placebo alongside lifestyle support—about 14.9% versus 2.4% of body weight. Results are group averages, not a prediction for any individual.

I'll be honest with you: other rcts have studied semaglutide in different populations and settings. STEP 2, for example, examined people with type 2 diabetes and overweight or obesity; average weight loss was lower than in STEP 1. STEP 4 included a continuation-versus-withdrawal phase: participants switched from semaglutide to placebo tended to regain weight, while those who continued treatment maintained or increased their loss. This highlights that obesity is often a chronic condition and that stopping treatment may affect weight.

Evidence of benefit does not mean the medication is safe for every person. Trials have eligibility rules and may not represent people with certain serious illnesses, pregnancy, or complex medication regimens. RCT results must be considered alongside product labeling, clinical assessment, and individual preferences.

Who should not take a GLP-1 medication?

People with a personal or family history of medullary thyroid carcinoma or MEN2

In the United States, semaglutide products carry a boxed warning based on thyroid C-cell tumors observed in rodents. Whether this risk applies to humans is unknown. Ozempic and Wegovy should not be used by people with a personal or family history of medullary thyroid carcinoma (MTC), a rare type of thyroid cancer, or by people with multiple endocrine neoplasia syndrome type 2 (MEN2). This is a key MEN2 contraindication under US labeling. Anyone unsure about a family history should discuss it with their prescriber before treatment.

People who have had a serious allergic reaction to the medicine

A person who has had a serious hypersensitivity reaction to semaglutide or an ingredient in the specific product should not take it again unless an appropriate specialist determines otherwise. Seek urgent medical care for symptoms such as difficulty breathing, swelling of the face or throat, or a severe widespread rash.

People who are pregnant, planning pregnancy, or breastfeeding

Weight-loss treatment is not appropriate during pregnancy. Wegovy labeling advises stopping semaglutide when pregnancy is recognized; for a planned pregnancy, it should xcelerategyms.com generally be stopped at least two months beforehand because it remains in the body for an extended period. A person taking semaglutide for diabetes should contact their diabetes care team promptly if pregnant or planning pregnancy, since glucose-management needs change and alternatives may be required.

Pregnancy and breastfeeding decisions need individualized medical advice. Information about semaglutide in human milk is limited, and product guidance may differ by formulation and country. Do not assume that breastfeeding makes treatment safe or unsafe in every circumstance. Discuss the potential benefits and risks with a clinician, including the needs of the infant and the reason for treatment.

People with certain significant medical conditions or treatment risks

Some conditions are not universal, formal contraindications, but may make treatment unsuitable or call for extra caution. A prescriber may recommend another option, specialist input, or closer monitoring for people with:

• Severe gastroparesis or major digestive problems: these medicines slow stomach emptying and may worsen symptoms. They are generally not recommended for severe gastroparesis.
• A history of pancreatitis: pancreatitis has been reported. It is not always an automatic exclusion, but the cause, recurrence risk, and alternatives should be discussed. Persistent severe abdominal pain requires urgent assessment.
• Gallstones or gallbladder disease: rapid weight loss and GLP-1 treatment can be associated with gallbladder problems. Prior disease warrants a conversation about risks and warning signs.
• Diabetic retinopathy: rapid improvement in blood glucose can temporarily worsen existing retinopathy in some people. Eye status and the pace of glucose improvement may need attention.
• Use of insulin or a sulfonylurea: combining these medicines can raise the risk of low blood sugar. A clinician may need to adjust doses and explain how to recognize and treat hypoglycemia.
• Planned anesthesia or deep sedation: delayed stomach emptying may increase the risk of stomach contents entering the lungs. Tell the surgical or anesthesia team about treatment; do not independently stop or continue it around a procedure.

People with type 1 diabetes should not use semaglutide as a replacement for insulin. Using it for purposes not approved in the person’s country, or combining it with another semaglutide product or another GLP-1 medicine, should only happen if a qualified prescriber specifically directs it.

Eligibility is not the same as suitability

Eligibility rules depend on the product, the reason for treatment, and the healthcare system. In the UK, NICE recommendations for semaglutide weight management have included use through specialist weight-management services for adults meeting specified BMI and health criteria. Under NICE technology appraisal TA875, the recommendation generally applies to adults with a BMI of at least 35 kg/m² and at least one weight-related comorbidity, with a lower BMI threshold potentially relevant for some ethnic groups. Adults with a BMI from 30 to below 35 kg/m² may be considered for referral to a specialist service, depending on the circumstances and pathway.

NICE guidance also sets conditions around specialist support, duration, and assessment of response; for example, treatment may be stopped if weight loss is less than 5% after six months on the highest tolerated dose. Recommendations and local access arrangements can change, and NICE guidance is not the same as US FDA labeling or insurance coverage. A person should check current local guidance and discuss their eligibility with a clinician.

Meeting a BMI threshold does not automatically mean a GLP-1 medicine is the right choice. Conversely, someone who does not meet a particular funding or program threshold may still benefit from a discussion about other evidence-based care.

Side effects and monitoring

Nausea, diarrhea, vomiting, constipation, and abdominal discomfort are among the common side effects. They may be more noticeable when starting treatment or increasing the dose. Smaller meals, eating more slowly, and following the prescriber’s dose-escalation plan may help, but persistent or severe symptoms should be reported rather than managed by changing the dose alone.

More serious problems can occur, although they are less common. Contact a healthcare professional promptly for symptoms such as persistent severe abdominal pain, repeated vomiting or inability to keep fluids down, signs of dehydration, or symptoms of gallbladder disease such as upper-right abdominal pain with fever or jaundice. Sudden vision changes, a severe allergic reaction, or symptoms of dangerously low blood sugar also need urgent attention.

What may be monitored Why it matters What to discuss Weight, appetite, and treatment goals To assess benefit, tolerability, and whether treatment remains worthwhile Expected progress, realistic goals, and what happens if treatment is stopped Blood glucose and diabetes medicines Glucose may improve, and some combinations increase low-blood-sugar risk Whether insulin or sulfonylurea doses need adjustment Digestive symptoms and hydration Ongoing vomiting or diarrhea can cause dehydration and other complications When symptoms need urgent care or a treatment review Eye health, especially with diabetes Rapid glucose improvement may affect existing diabetic retinopathy Current eye-care follow-up and any new vision symptoms Pregnancy plans and procedures Medication timing may need to change before pregnancy or anesthesia When to stop or restart, directed by the clinical team

Be cautious about online marketplaces and social media

Do not buy semaglutide from online marketplaces, sellers without a valid prescription, or informal sources promoted through social media channels. Products may be counterfeit, improperly stored, contaminated, or incorrectly labeled. Compounded preparations are not the same as FDA-approved products and may have different risks. Use a licensed pharmacy and verify that the prescriber and product are legitimate. If you have already used a product from an uncertain source, contact a healthcare professional or pharmacist and keep the packaging for review.

Questions to ask before starting

1. What is the specific treatment goal, and is this product approved for that purpose where I live?
2. Do my personal or family medical history, including MTC or MEN2, rule it out?
3. How might it interact with my diabetes medicines or affect digestive, gallbladder, eye, or kidney-related care?
4. What side effects should prompt a call, urgent care, or a change in treatment?
5. How will we measure progress, and what is the plan if the medicine is ineffective, poorly tolerated, or stopped?

The bottom line

GLP-1 medications can be effective for some people, but they are not appropriate for everyone. In particular, US semaglutide labeling contraindicates use with a personal or family history of medullary thyroid carcinoma or MEN2, and pregnancy requires prompt medical review. Other health conditions and medicines may call for caution, alternatives, or close monitoring. A qualified prescriber can weigh the evidence, current local guidance, and your individual circumstances to help decide whether treatment is a safe and suitable option.